Choice of Hormone Assay to Monitor Feminizing Gender-Affirming Hormone Therapy
An erratum to this article was published (Endocr Pract, Aug 2026 ↗)
Authors' conclusion
To monitor feminizing GAHT, it may be reasonable to favor target T concentrations over E2 concentrations in patients with testes and to consider LH concentrations in patients without testes who are not taking gonadotropin-releasing hormone agonists.
Study context
- Population
- Transfeminine individuals prescribed estradiol for feminizing gender-affirming hormone therapy (GAHT)
- Participants
- 9,916 individuals
- Outcome
- Association between most recent serum T, E2, LH and FSH concentrations during feminizing GAHT
Main finding
As reported in the abstract
Correlations among T, E2, LH and clinical parameters
- Changes in T inversely correlated with changes in E2
- P < .001
- Orchiectomy, age and spironolactone use associated with changes in T, but not E2
- P < .001
- Changes in T correlated with changes in luteinizing hormone (LH)
- P < .05
Observational data: associations, not effects.
Original publication
Choice of Hormone Assay to Monitor Feminizing Gender-Affirming Hormone Therapy. Endocr Pract. Published 11 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →